Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Kezar Life Sciences, Inc.

< Previous 1 2 Next >
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.